Background: Hereditary pancreatitis is caused by mutations in human cationic trypsinogen. Chymotrypsin C is a proteolytic regulator of trypsinogen activation. Results: Clinically relevant trypsinogen mutations increase autoactivation in the presence of chymotrypsin C. Conclusion: Pathological trypsinogen activation in hereditary pancreatitis is dependent on chymotrypsin C.
Mutations in human cationic trypsinogen (PRSS1) cause autosomal dominant hereditary pancreatitis.
Increased intrapancreatic autoactivation of trypsinogen mutants has been hypothesized to initiate the disease. Autoactivation of cationic trypsinogen is proteolytically regulated by chymotrypsin C (CTRC), which mitigates the development of trypsin activity by promoting degradation of both trypsinogen and trypsin. Paradoxically, CTRC also increases the rate of autoactivation by processing the trypsinogen activation peptide to a shorter form. The aim of the present study was to investigate the effect of CTRC on the autoactivation of clinically relevant trypsinogen mutants. We found that in the presence of CTRC, trypsinogen mutants associated with classic hereditary pancreatitis (N29I, N29T, V39A, R122C and R122H) autoactivated at increased rates and reached markedly higher active trypsin levels than wildtype cationic trypsinogen. The A16V mutant, known for its variable disease penetrance, exhibited a smaller increase in autoactivation. The mechanistic basis of increased activation was mutation-specific and involved resistance to degradation (N29I, N29T, V39A, R122C, and R122H) and/or increased N-terminal processing by CTRC (A16V and N29I). The observations indicate that hereditary pancreatitis is caused by CTRC-dependent dysregulation of cationic trypsinogen autoactivation, which results in elevated trypsin levels in the pancreas.
Hereditary chronic pancreatitis is an autosomal dominant genetic disorder characterized by incomplete penetrance and variable expressivity. In approximately half of the affected families the disease is caused by heterozygous mutations in the serine protease 1 (PRSS1) gene which encodes human cationic trypsinogen [1] [2] [3] [4] . The human pancreas secretes three isoforms of trypsinogen and the cationic isoform contributes circa two thirds of the trypsinogen content in the pancreatic juice. In the large majority of hereditary pancreatitis families worldwide the causative mutation is either R122H (~70%) or N29I (~20%). Less frequently, the same amino-acid positions are altered by mutations R122C (~3%) and N29T (<1%), respectively. In addition, a large number of rare PRSS1 mutations have been identified not only in kindreds with hereditary pancreatitis but also in patients with sporadic idiopathic pancreatitis. Many of these most likely represent 2 harmless variants or mutations with variable or low disease penetrance [5] .
Functional studies using recombinant cationic trypsinogen mutants demonstrated that mutations N29I, N29T and R122H increased autoactivation (trypsin-mediated trypsinogen activation), albeit to a modest degree [6] [7] [8] . Convincing evidence that increased autoactivation is an important mechanism in hereditary pancreatitis came from studies on a subset of rare mutations (D22G, K23R and K23I_I24insIDK) that affect the trypsinogen activation peptide and cause a dramatic increase in autoactivation [9] [10] [11] . However, activation peptide mutations did not seem to cause more severe disease and the apparent lack of correlation between biochemical and clinical phenotypes associated with different trypsinogen mutations remained puzzling. An early study found that mutation R122C caused loss of function due to misfolding, however, this proved to be an artifact of the in vitro refolding procedure used at the time [12] . On the other hand, mutant R116C, another cysteine mutant associated with hereditary pancreatitis, was shown to misfold and elicit endoplasmic reticulum (ER) stress in HEK 293T cells, suggesting that mutation-induced misfolding and consequent ER stress may be an alternative disease mechanism, unrelated to trypsinogen activation [13] . Whether or not mutant R116C misfolds in acinar cells is still uncertain and the role of ER stress in pancreatitis, although intensely researched, remains speculative.
A number of recent studies from our laboratory demonstrated that cationic trypsinogen and trypsin are under the regulation of chymotrypsin C (CTRC) in humans. First, we found that CTRC stimulates autoactivation of cationic trypsinogen by processing the trypsinogen activation peptide to a shorter form, which is more readily cleaved by trypsin [14] . The A16V cationic trypsinogen mutation, which changes the Nterminal residue of the activation peptide, increases the rate of N-terminal processing by CTRC. Subsequently, we found that CTRC promoted degradation of cationic trypsin by a mechanism that involved cleavage of the Leu81-Glu82 peptide bond in the calcium binding loop and an autolytic cleavage by trypsin at the Arg122-Val123 peptide bond [15] . Both cleavages are required and mutation of either Leu81 or Arg122 blocks degradation. CTRC mediated cleavage at Leu81 is calcium-dependent and millimolar concentrations of calcium protect trypsin against degradation. Finally, we and others obtained genetic evidence that loss-of-function variants of CTRC increase the risk for chronic pancreatitis in humans, indicating that CTRC plays an important protective role in the pancreas against premature trypsinogen activation [16] [17] [18] . The CTRC-mediated effects on trypsinogen and trypsin are highly specific, and other chymotrypsin or elastase isoforms have no such activity.
We also observed that CTRC degraded cationic trypsinogen at a faster rate than cationic trypsin [15] , suggesting that CTRC might regulate mainly the activation of trypsinogen to trypsin rather than controlling active trypsin levels through degradation. Autoactivation of cationic trypsinogen and its hereditary pancreatitisassociated mutants have never been studied in the presence of CTRC. In this study, therefore, we undertook these experiments following the hypothesis that pancreatitis-associated mutants may exert their effect in a CTRC-dependent manner. The findings reveal a prominent biochemical phenotype shared by all diseasecausing mutants which involves altered regulation by CTRC and, as a consequence, strongly increased trypsinogen activation in the presence of CTRC.
EXPERIMENTAL PROCEDURES
Nomenclature. Amino acid residues in human cationic trypsinogen (protease serine 1, PRSS1) are numbered starting with the initiator methionine of the primary translation product; according to the recommendations of the Human Genome Variation Society.
Expression plasmids and mutagenesis. Construction of the pTrapT7-intein-Hu1, pTrapT7-Hu1-K23Q and pcDNA3.1(-)-Hu1 expression plasmids harboring the coding sequence for human cationic trypsinogen (Hu1) was reported previously [6, 7, 19, 20] . In an earlier publication mutation K23Q was denoted as K15Q, using the conventional chymotrypsin numbering [20] . In the pTrapT7-intein-Hu1 plasmid the native N terminus of human cationic trypsinogen (Ala-Pro-Phe) is fused to the C terminus of a miniintein [19] . In the pTrapT7-Hu1-K23Q plasmid the N-terminal sequence of trypsinogen was 3 changed to Met-Ala-Phe-Pro-Val due to cloning manipulations [20] . Mutations were introduced using overlap-extension PCR mutagenesis and verified by DNA sequencing of the entire gene.
Expression, purification and activation of human CTRC. Construction of the pcDNA3.1(-) CTRC expression plasmid was reported earlier [15] . In the present study, a 10His affinity tag was engineered onto the C terminus of the protein. CTRC was expressed in HEK 293T cells with transient transfection as described [21] . Approximately 900 mL conditioned medium was used for purification on a Ni-NTA Superflow Cartridge (Qiagen) equilibrated with NPI-20 buffer [50 mM NaH 2 PO 4 , 300 mM NaCl, 20 mM imidazole (pH 8.0)]. The medium was loaded onto the column at 4 mL/min flow rate using a loading pump and the column was washed with NPI-20 buffer until the absorbance at 280 nm returned to baseline. CTRC was eluted with NPI-250 buffer [50 mM NaH 2 PO 4 , 300 mM NaCl, 250 mM imidazole (pH 8.0)] at 2 mL/min flow rate and 5 mL fractions were collected. Aliquots (100 µL) of the fractions were analyzed by 15% SDS-PAGE and Coomassie blue staining and peak fractions were pooled and dialyzed for 24 h against two changes of 3.5 liters of 50 mM NaH 2 PO 4 (pH 8.0) buffer containing 300 mM NaCl. The dialyzed CTRC proenzyme solution was concentrated using a Vivaspin concentrator (10 kDa MWCO). CTRC zymogen was activated with human cationic trypsin and CTRC concentrations were determined by active site titration with ecotin as described previously [22] . The final working CTRC stock solution was diluted to 500 nM concentration in 0.1 M Tris-HCl (pH 8.0) and 0.05% Tween-20.
Expression and purification of human cationic trypsinogen. Wild-type and mutant trypsinogens were expressed as intein fusion proteins in aminopeptidase P deficient E. coli strain LG-3, as described previously [19, 23] . After spontaneous self-cleavage, the fusion protein gives rise to cationic trypsinogen with a homogeneous, authentic N-terminal sequence. K23Q trypsinogens were expressed in E. coli BL21(DE3) with the exception of the A16V, K23Q double mutant, which was made as an intein fusion and expressed in LG-3. Trypsinogen was solubilized from the inclusion bodies, refolded in vitro and purified by ecotin affinity chromatography according to published protocols [6, 7, 19, 23, 24] . Mutant R122C, which is prone to misfolding in vitro [12] , was expressed in HEK 293T cells by transient transfection. The growth medium contained 1 mM concentration of benzamidine to prevent autoactivation. Trypsinogen was purified from 400 mL conditioned medium by ecotin chromatography. Concentrations of trypsinogen preparations were calculated from their UV absorbance at 280 nm using the extinction coefficient 37,525 M -1 cm -1 .
Trypsin activity assay. Trypsin activity was measured in 0.1 M Tris-HCl (pH 8.0) containing 1 mM CaCl 2 and 0.05% Tween-20 using the chromogenic trypsin substrate N-CBZ-Gly-ProArg-p-nitroanilide at 0.15 mM final concentration in 200 µL final volume at 22 o C. Typically, a 2 µL sample was mixed with 48 µL assay buffer and the reaction was started by adding 150 µL substrate dissolved in the same buffer. The release of the yellow p-nitroaniline was followed for 1 min at 405 nm in a SpectraMax Plus384 microplate reader (Molecular Devices).
Gel electrophoresis and densitometry. Trypsinogen samples were precipitated with trichloroacetic acid (10% final concentration), the precipitate was recovered by centrifugation, dissolved in 20 µL Laemmli sample buffer containing 100 mM dithiothreitol (final concentration), and heat-denatured at 95 °C for 5 min. Electrophoretic separation was performed on 15% SDS-PAGE mini gels in standard Trisglycine buffer. Gels were stained with 0.5% Brilliant Blue R dissolved in 40% methanol, 10% acetic acid for 30 min, and destained with 30% methanol, 10% acetic acid overnight. Gels were dried between two layers of cellophane and scanned at 300 dpi resolution in gray-scale mode. Quantitation of bands was carried out with the Quantity One 4.6.9 (Bio-Rad) software. Rectangles were drawn around each band of interest, and an identical rectangle was used in each lane for background subtraction. 4 relative to other mammalian trypsinogens studied so far [25] . When a trypsinogen preparation at 1 µM concentration was incubated with 10 nM trypsin at 37 o C, at pH 8.0, in the presence of 1 mM Ca 2+ , conversion to trypsin was essentially complete within 40 min ( Fig 1A) and final trypsin activity remained stable. Addition of low concentrations (1 -25 nM) of human CTRC to this reaction resulted in a slightly increased rate of autoactivation with reduced final trypsin levels that were inversely proportional to the CTRC concentration present and slowly decreased over time from their peak value ( Fig 1A) . The small increase in the rate of autoactivation was due to Nterminal processing by CTRC [14] ; suppression of final trypsin levels was caused by CTRC-mediated trypsinogen degradation, and the slow decrease in trypsin activity was due to trypsin degradation by CTRC [15] . Previously, we determined that CTRC-dependent trypsin degradation involves cleavages at Leu81 (by CTRC) and at Arg122 (by trypsin) [15] . To confirm that the same cleavages are required for trypsinogen degradation during autoactivation in the presence of CTRC, mutants L81A and R122A were studied (Figs 1B and 1C). In the absence of CTRC, autoactivation of mutant L81A was identical to that of wild type, whereas mutant R122A showed a small increase in the rate (cf. Figs 1A, 1B and 1C). Thus, as expected, these mutations had no major impact on autoactivation per se. In contrast, when assayed in the presence of 5 nM or 25 nM CTRC, both mutations protected against CTRC-induced trypsinogen degradation and resulted in rapid autoactivation to high trypsin levels (Figs 1B and 1C). Mutant L81A autoactivated to the same trypsin levels with or without CTRC (Fig 1B) , whereas mutant R122A showed only a small CTRC-dependent decrease in the final trypsin activity (Fig 1C) . Furthermore, due to the lack of degradation, the effect of CTRC-mediated N-terminal processing became much more apparent, i.e. rates of autoactivation were noticeably increased. These results indicate that CTRC regulates autoactivation of human cationic trypsinogen and mutations that interfere with these processes can have profound effects on trypsin levels resulting from trypsinogen activation. Consequently, we hypothesized, naturally occurring hereditary-pancreatitis associated cationic trypsinogen mutations might exert their effect through this mechanism.
Autoactivation of cationic trypsinogen mutants in the presence of CTRC. Mutations of Arg122 (R122C and R122H) are the clinically most frequent pancreatitis-causing genetic variants. Since both mutations block the trypsin-mediated cleavage of the Arg122-Val123 peptide bond, CTRC-dependent trypsinogen degradation should be impaired resulting in increased autoactivation, in a manner that was already observed with the R122A non-natural mutation in Fig 1C. Because mutant R122C tends to misfold during the in vitro refolding procedure used [12] , this mutant was expressed in transiently transfected HEK 293T cells and purified from the conditioned medium. As an appropriate control, a wild-type cationic trypsinogen preparation was also produced by the same method. When tested in the absence of CTRC, both mutations R122C and R122H increased the rate of autoactivation of cationic trypsinogen to a modest extent, 1.2-fold and 1.5-fold, respectively (Fig 2A) . In contrast, autoactivation of mutants R122C and R122H was dramatically increased in the presence of CTRC, relative to wild type (Figs 2B and 2C). Trypsin levels remained stable over the time course studied, consistent with previous observations that trypsin mutants R122C and R122H were resistant to degradation by CTRC [15] . While in the absence of CTRC rates of autoactivation can be estimated assuming the reaction proceeds as "trypsinogen + trypsin = 2 trypsin" and degradation is negligible, the same formula cannot be used to describe autoactivation in a quantitative manner once CTRC is present in the system. From a biological perspective, the peak trypsin value and the time to reach the maximum amplitude seem intuitively important. Therefore, we compared the area under the curve between wild type and mutants from time zero until the time the wild type reached its peak trypsin activity. We found that mutants R122C and R122H showed 3.3-fold and 3.5-fold higher values than wild type in the presence of 5 nM CTRC and these values increased to 5.0-fold and 4.8-fold, respectively, in the presence of 25 nM CTRC. The dependence of these values on the CTRC concentration suggests that the differences between wild-type and mutant trypsinogens may be even larger under physiological conditions where CTRC concentrations are higher than used experimentally (see Discussion).
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Mutations of Asn29 (N29I and N29T) are the second most prevalent hereditary-pancreatitisassociated changes in cationic trypsinogen. In the absence of CTRC, mutation N29I slightly (1.5-fold) increased the rate of autoactivation, whereas mutation N29T had a somewhat more pronounced (2.5-fold) stimulating effect (Fig 2A) . In the presence of CTRC, when compared to wild-type trypsinogen, autoactivation was strongly accelerated by both mutations, resulting in remarkably higher trypsin levels ( Figs 2B and 2C ). For the N29I mutant the area under the curve values were 4.1-fold higher than wild type in the presence of both CTRC concentrations tested. For the N29T mutant the same values were 3.7-fold and 5.2-fold higher than wild type at 5 nM and 25 nM CTRC, respectively. In contrast to mutants R122C and R122H, trypsin mutants N29I and N29T were prone to degradation by CTRC and trypsin levels steadily decreased over time. Interestingly, trypsin degradation showed mutation-specific differences as N29I trypsin was more readily degraded by CTRC than N29T trypsin, which had superior stability, particularly at higher CTRC concentrations (Fig 2C) .
The results presented in Fig 2 indicate that mutations associated with classic autosomal dominant hereditary pancreatitis exhibit a similar biochemical phenotype in the presence of CTRC that is characterized by increased rates of trypsinogen activation with high levels of trypsin generated. To extend these studies, we tested the effect of mutation V39A on trypsinogen autoactivation. This mutation was described in a single hereditary pancreatitis family in Italy, where it showed convincing segregation with the disease in seven family members [26] . In the absence of CTRC, the V39A mutation had no significant effect on trypsinogen autoactivation, whereas in the presence of CTRC a large increase in autoactivation was observed when compared to wild-type cationic trypsinogen (Fig 3) . Mutant V39A autoactivated at a slower rate than mutant R122H and final trypsin levels approached but remained lower than those seen with the R122H mutant. The area under the curve values were 2.1-fold and 2.7-fold higher than wild type in the presence of 5 nM and 25 nM CTRC, respectively (.c.f. mutant R122H, 2.9-fold and 4.7-fold in the same experiment). These quantitative differences notwithstanding, mutant V39A exhibited a biochemical phenotype similar to the more frequent pancreatitis-associated mutations.
Mutation A16V is associated with variable disease penetrance and was identified not only in hereditary pancreatitis families but also in sporadic cases with no family history, suggesting a weaker biochemical phenotype [27, 28] . The mutation is found in ~3% of PRSS1 mutation positive pancreatitis cases, although a recent study from Denmark reported higher regional occurrence [29] . The A16V mutation alters the N-terminal aminoacid residue of the trypsinogen activation peptide. Amino acid 16 is the first residue of mature trypsinogen, as the secretory signal peptide (amino acids 1-15) is cleaved off during ER entry. Because the activation peptide is released during the activation process, mutation A16V is not present in active trypsin and thus cannot alter trypsin function. Previously, we demonstrated that mutation A16V increased N-terminal processing of the trypsinogen activation peptide by CTRC at the Phe18-Asp19 peptide bond by 4-fold, which is expected to result in increased autoactivation [14] . Here, we found that in the absence of CTRC, mutation A16V had no effect on trypsinogen autoactivation (Fig 3A) , as demonstrated previously. In the presence of CTRC, the rate of autoactivation was increased measurably relative to wild type, albeit to a lesser degree than observed with the strongly disease penetrant mutations ( Figs 3B and 3C ). The area under the curve values were 1.8-fold and 2.0-fold higher than wild type in the presence of 5 nM and 25 nM CTRC, respectively. Thus, the variable clinical presentation of the A16V mutation is consistent with its milder biochemical phenotype.
Mechanistic basis of increased autoactivation in the presence of CTRC. The results presented above indicate that proteolytic regulation of cationic trypsinogen mutants by CTRC is altered in such a manner that results in more robust trypsinogen activation. In theory, trypsinogen mutations can cause increased autoactivation by at least four different mechanisms: (i) increased trypsin-mediated cleavage of the activation peptide caused by either a direct mutational effect or (ii) indirectly, by increased N-terminal processing at the Phe18-Asp19 peptide bond by CTRC; (iii) impaired trypsinogen degradation during autoactivation due to slower cleavage of 6 the Leu81-Glu82 peptide bond by CTRC or (iv) decreased cleavage of the Arg122-Val123 peptide bond by trypsin. In the following experiments, these potential mechanisms were explored.
(i) As presented in Figs 2A and 3A and reported previously, most mutations studied here had little direct effect on autoactivation [6, 7, 19] . Mutations R122H and N29I increased the rate of autoactivation by 1.5-fold, and mutation R122C by 1.2-fold. Mutations A16V and V39A had no measurable stimulating effect. The only exception was mutation N29T, which increased the rate of autoactivation by approximately 2.5-fold.
(ii) N-terminal processing of cationic trypsinogen by CTRC removes the three Nterminal amino-acid residues from the activation peptide, which results in a small but detectable shift on SDS-polyacrylamide gels run under nonreducing conditions. Using this assay, we previously found that mutations A16V and N29I increased CTRC-mediated N-terminal processing of cationic trypsinogen by 4-fold and 1.4-fold, respectively [14] . In our current experiments we confirmed these findings and found even stronger effects after densitometric analysis (Fig 4) : Thus, mutation A16V increased the rate of N-terminal processing 5.8-fold and mutation N29I by 2.6-fold, relative to wild type. On the other hand, mutations V39A, R122C and R122H had no appreciable effect on this CTRC activity. Interestingly, mutant N29T was processed slightly (1.3-fold) slower than wild-type trypsinogen (Fig 4) .
(iii) CTRC-mediated degradation of cationic trypsinogen is initiated by cleavage of the Leu81-Glu82 peptide bond in the calcium binding loop [15] . This cleavage is rapid when the binding loop is unoccupied, whereas calcium binding inhibits cleavage (K D ~20 µM), with complete inhibition requiring 10 mM or higher concentrations. Experimentally, the reaction is best followed in the absence of calcium when full time courses of degradation can be measured using SDS-PAGE and densitometry. Fig 5 demonstrates that the rate of cleavage by CTRC at Leu81 became measurably reduced in mutants N29I (2.5-fold), N29T (3.6-fold), V39A (1.5-fold), R122C (2.1-fold) and R122H (3.1-fold), whereas it was essentially unchanged in mutant A16V.
(iv) Trypsin-mediated cleavage of the Arg122-Val123 peptide bond is required for CTRCdependent trypsinogen degradation [15] . Cleavage of this peptide bond by trypsin does not proceed to completion but due to trypsin-mediated peptidebond re-synthesis a dynamic equilibrium is reached between the uncleaved and cleaved trypsinogen forms [20] . To investigate the effect of pancreatitis-associated mutations on the ability of trypsin to cleave trypsinogen at Arg122, we used a stable, non-activable trypsinogen in which the activating site was mutated (K23Q) [20] . Mutations were transferred to the K23Q background and trypsinogen preparations at 2 µM concentration were digested with 10 nM trypsin in the presence of low calcium concentrations (5 µM) which favor cleavage. Time courses of digestion were analyzed by SDS-PAGE and densitometry (Fig 6) . Since the two products of the cleavage reaction co-migrate as a single band, measurement of the hydrolysis equilibrium between intact and cleaved trypsinogen is straightforward. The equilibrium mixture of wild-type trypsinogen contained 35% intact and 65% cleaved forms. Not surprisingly, mutations R122H and R122C (not shown) completely blocked cleavage at Arg122. Mutations N29I and N29T slightly (1.2-fold and 1.3-fold, respectively) decreased the rate of cleavage and increased the equilibrium levels of uncleaved trypsinogen to 40% and 45%, respectively. Remarkably, mutation V39A decreased the rate of cleavage at least 3-fold and shifted the cleavage equilibrium towards the uncleaved form (~50%). Finally, as expected, mutation A16V had no effect on this reaction (not shown).
Taken together, it appears that the mechanistic basis of increased trypsinogen autoactivation in the presence of CTRC is mutation-specific and may involve a combination of relatively smaller effects, as summarized in Table 1 .
Effect of pancreatitis-associated mutations on trypsin stability. Historically, the biochemical effects of pancreatitis-associated trypsinogen mutations used to be interpreted in the context of trypsin stability [1] . In light of the present and other recent data the primary effects of trypsinogen mutations should be considered in terms of trypsinogen autoactivation. Nonetheless, final trypsin levels achieved during trypsinogen autoactivation are also influenced by trypsin stability to a lesser degree. As seen in Fig 1A, peak trypsin levels slowly decline due to CTRC-7 mediated trypsin degradation and mutations N29T, R122C and R122H seem to render trypsin more resistant to CTRC-mediated degradation, as indicated by the sustained trypsin plateau phase in Figs 2B and 2C. To compare the effect of pancreatitis-associated mutations on trypsin degradation in a more quantitative manner, we activated wild-type and mutant trypsinogens with human enteropeptidase and followed the loss of trypsin activity after addition of 25 nM CTRC. We performed these experiments in the presence of low calcium concentrations (5 µM) to allow the reactions to proceed at a higher rate. Fig 7  demonstrates that, relative to wild-type trypsin, inactivation of trypsin mutants R122C and R122H proceeded at 11-fold slower rates. Mutants N29T and V39A were degraded approximately 3-fold slower than wild-type trypsin, whereas degradation of mutant N29I was comparable to wild type (see also Table 1 ). Note that mutation A16V has no effect on trypsin stability as this mutation is not present in active trypsin.
DISCUSSION
In the present study we demonstrate that cationic trypsinogen mutations that are associated with classic autosomal dominant hereditary pancreatitis all exhibit markedly increased autoactivation in the presence of CTRC. These findings mark the successful conclusion of a more than decade-long quest for the common biochemical defect caused by hereditary pancreatitis-associated mutations. Increased autoactivation was proposed as a unifying mechanism as early as 2000, however, clinically common mutations N29I and R122H had a relatively minor, not particularly convincing effect [7] (also see Fig 2A) . Even more confusing was the observation that activation peptide mutations D22G, K23R and K23I_I24insIDK stimulated autoactivation in a dramatic manner yet still caused essentially the same clinical disease as mutations N29I or R122H [9] [10] [11] . Thus, there appeared to be no correlation between the biochemical phenotype and the biological effect. The results presented here resolve this apparent contradiction and clearly demonstrate a very similar biochemical phenotype for the highly penetrant, hereditary pancreatitis-associated mutations N29I, N29T, V39A, R122C and R122H. Furthermore, consistent with its variable disease penetrance, mutant A16V was shown to exhibit a smaller increase in autoactivation than mutants causing hereditary pancreatitis.
Unexpectedly, investigations into the mechanistic basis of increased autoactivation revealed several mutation-specific mechanisms, often acting in concert (see Table 1 ). (i) Even in the absence of CTRC, mutations N29I, N29T, R122C and R122H had a direct stimulatory effect on the rate of autoactivation, which ranged from 1.2 to 2.5-fold. These relatively small effects represent increased proteolytic accessibility of the activation peptide caused by the mutations. (ii) Mutations A16V and N29I increased the rate of Nterminal processing of the trypsinogen activation peptide by CTRC 5.8-fold and 2.6-fold, respectively. N-terminal processing stimulates trypsin-mediated cleavage of the activation peptide (i.e. autoactivation) by relieving an electrostatic inhibitory interaction between the tetra-aspartate motif in the activation peptide and Asp218 on trypsin [14] . Notably, this is the only biochemical change caused by mutation A16V. (iii) CTRC-dependent degradation of cationic trypsinogen requires cleavages by CTRC at Leu81 and by trypsin at Arg122. With the exception of A16V, all mutations affected both of these cleavages. With respect to cleavage at Leu81 by CTRC, mutations N29I, N29T, V39A, R122C and R122H all had a modest inhibitory effect that ranged from 1.5-fold to 3.6-fold. (iv) With respect to the autolytic cleavage at Arg122, mutations R122C and R122H blocked this reaction, whereas mutation V39A decreased the rate of cleavage by 3-fold. Mutations N29I and N29T also had a small but measurable negative effect on the rate of cleavage. Furthermore, all mutations shifted the cleavage equilibrium towards uncleaved trypsinogen, to various degrees. The altered cleavage at Arg122 seemed to be the dominant functional effect for mutations R122C, R122H and possibly V39A. As summarized in Table 1 , the synergestic action of these four mechanisms is best seen with mutant N29I, where all four mechanisms increase autoactivation to a relatively small extent but their cumulative effect becomes striking (see Fig 2B) . Three of the four mechanisms are operational in mutants N29T, R122C and R122H and two in mutant V39A ( Table 1) . As pointed out above, the only exception is mutant A16V where a single mechanism is responsible for the disease-8 associated phenotype of increased autoactivation. Finally, four mutations (N29T, V39A, R122C and R122H) also reduced CTRC-mediated trypsin degradation, which may also contribute to the peak trypsin levels achieved during autoactivation. However, one of the key messages of this study is that the pathogenic effects of pancreatitisassociated trypsinogen mutations should be interpreted, first and foremost, in the context of trypsinogen autoactivation and not trypsin stability, as suggested earlier [1] .
The structural basis for the decreased cleavage at Leu81 by CTRC and at Arg122 by trypsin in the trypsinogen mutants is not readily apparent but available crystal structures may give some clues. In the bovine trypsinogen X-ray structures (2TGD and 1TGN), the side chains of Arg122 (Arg117 in chymotrypsin numbering, chymo#), Asn84 (chymo# Asn79) and Asn33 (chymo# Asn25) are within "striking distance" (~4Å or less) of each other, suggesting that subtle structural changes altering these interactions may influence cleavage at Arg122 (Fig 8) . Since Leu81 in human cationic trypsinogen lies in proximity to Asn84, the same mechanism may account for altered cleavage at Leu81. Mutations N29I, N29T and possibly V39A may affect Asn33, whereas mutations R122C and R122H may affect both Asn33 and Asn84.
The disease-relevant compartment in the pancreas where increased trypsinogen activation might take place in hereditary pancreatitis is unknown, but the pancreatic juice within the excretory ducts seems to be the best candidate. This notion is supported by the observations that mutations in the cystic fibrosis transmembrane conductance regulator (CFTR), expressed in duct epithelia, or anatomical variations in duct morphology increase the risk for chronic pancreatitis [30] . The autoactivation experiments presented here were performed in the presence of 1 mM CaCl 2 . In human pancreatic juice total calcium concentrations were reported between 0.2 mM and 0.9 mM with higher values found in patients with chronic pancreatitis [31] [32] [33] . One study reported ionized calcium concentrations at 0.3 mM, with 0.6 mM total calcium [32] . We chose to use 1 mM calcium in our experiments, because under these conditions trypsinogen autoactivation is well measurable with high trypsin signal even in the presence of CTRC. At slightly lower calcium concentrations that may prevail in the pancreatic juice autoactivation reactions would proceed with similar kinetics but with a smaller amplitude. Another important factor to consider is the CTRC concentrations used. CTRC is secreted in a zymogen form (chymotrypsinogen C) to the pancreatic juice at levels that are approximately 20-fold lower than those of cationic trypsinogen, as estimated by immunoblotting using purified proenzymes as standards (Z. Rónai, MST unpublished observations). CTRC has to be activated by trypsin, and this activating cleavage reaction is at least 100-fold faster than trypsinmediated trypsinogen activation (A. Geisz, MST unpublished observations). Consequently, small amounts of trypsin generated in the pancreatic juice can preferentially activate CTRC before trypsinogen autoactivation would progress. We performed our experiments at lower CTRC-totrypsinogen ratios (1:200 and 1:80) than one would expect to find during premature trypsinogen activation in the pancreas. It is likely that in normal pancreatic juice CTRC-dependent protection against premature autoactivation is more effective and development of trypsin activity is much more dampened than indicated in our autoactivation figures. Under these conditions, the higher autoactivation of mutant trypsinogens seen in our experiments would manifest as increased likelihood of appearance of trypsin activity. Such a scenario is consistent with the clinical course of hereditary pancreatitis which involves recurrent acute attacks of pancreatitis with symptom free intervals.
In summary, we demonstrated that mutations associated with hereditary pancreatitis alter CTRC-dependent proteolytic regulation of human cationic trypsinogen and result in markedly increased autoactivation. The findings suggest that targeted therapy for the management of pancreatitis risk should focus on continuous, longterm suppression of trypsinogen autoactivation.
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